Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven ...

Precision Bb Targeting, Robust Efficacy, Transfusion Independence, Excellent Safety in Phase II PNH Study, and Subcutaneous AdministrationKey ...

Junshi Biosciences has received acceptance from China’sNational Medical Products Administration (NMPA) for toripalimab ...

Xiaoping Wu and Jicheng Yang of Wanhuida Intellectual Property analyse an invalidation decision that addresses how dosage and administration features affect the inventiveness assessment of pharmaceuti ...

Risankizumab showed high rates of clinical remission and endoscopic response when administered as subcutaneous induction therapy for moderate to severe CD.

A new study published in the journal of BMC Nephrology showed that subcutaneous and intravenous epoetin showed similar ...

Biocon earns USFDA nod for Liraglutide injection, boosting its diabetes drug portfolio. Explore investment opportunities now!

Compounded NAD+ Telehealth Access, FDA Classification, Pharmacy Sourcing Standards, Prescription Requirements, and Consumer ...

Approval was supported by adult HS and psoriasis clinical trials, pharmacokinetic modeling, and data from established pediatric indications. The Food and Drug Administration (FDA) has approved ...

Olanzapine long-acting injectable (LAI) suspension (TEV-'749) has the potential to offer the efficacy of olanzapine in a once-monthly, subcutaneous formulation1If approved, TEV-'749 could help address ...

U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA) said on Friday that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for olanzapine extended-release ...